SQI Diagnostics (TSXV:SQD.H) - Hisse Senedi Fiyatı, Haberler ve Analizler

SQD.H Stoklara Genel Bakış

A precision medicine company, discovers, develops, and commercializes rapid diagnostic testing services for healthcare providers, patients, and consumers worldwide. Daha fazla detay

SQD.H temel anali̇z
Kar Tanesi Skoru
Değerleme	2/6
Gelecekteki Büyüme	0/6
Geçmiş Performans	0/6
Finansal Sağlık	0/6
Temettüler	0/6

Risk Analizi

Anlamlı bir piyasa değeri yok ( CA$6M )

Negatif hissedar öz sermayesi

Hisse senetleri oldukça likit değildir

Son mali raporlar bir yıldan daha eskidir

+ 2 daha fazla risk

SQI Diagnostics Inc. Rakipler

Scryb

CNSX:SCYB

CA$4.8m

ASEP Medical Holdings

CNSX:ASEP

CA$3.8m

Frequency Exchange

TSXV:FREQ

CA$6.6m

Evome Medical Technologies

TSXV:EVMT

CA$11.2m

Fiyat Geçmişi ve Performans

için tüm zamanların en yüksek seviyelerinin, değişikliklerin ve fiyat düşüşlerinin özeti SQI Diagnostics
Tarihsel hisse senedi fiyatları
Güncel Hisse Fiyatı	CA$0.015
52 Haftanın En Yüksek Seviyesi	CA$0.02
52 Haftanın En Düşük Seviyesi	CA$0.015
Beta	-0.38
11 Aylık Değişim	n/a
3 Aylık Değişim	n/a
1 Yıllık Değişim	n/a
33 Yıllık Değişim	-90.91%
5 Yıllık Değişim	-88.00%
Halka arzdan bu yana değişim	-99.23%

Son Haberler & Güncellemeler

Recent updates

If You Had Bought SQI Diagnostics (CVE:SQD) Stock A Year Ago, You Could Pocket A 246% Gain Today

Dec 22

Is SQI Diagnostics (CVE:SQD) Using Debt Sensibly?

Nov 17

Hissedar Getirileri

	SQD.H	CA Medical Equipment	CA Pazar
7D	0%	-1.4%	2.2%
1Y	n/a	2.5%	23.4%

Getiri vs. Endüstri: SQD.H un Canadian Medical Equipment sektörüne göre nasıl performans gösterdiğini belirlemek için yeterli veri yok.

Getiri vs Piyasa: SQD.H un Canadian Piyasasına göre nasıl performans gösterdiğini belirlemek için yeterli veri yok.

Fiyat Oynaklığı

Is SQD.H's price volatile compared to industry and market?
SQD.H volatility
SQD.H Average Weekly Movement	n/a
Medical Equipment Industry Average Movement	13.3%
Market Average Movement	8.3%
10% most volatile stocks in CA Market	17.7%
10% least volatile stocks in CA Market	2.9%

İstikrarlı Hisse Senedi Fiyatı: SQD.H son 3 ayda önemli bir fiyat oynaklığı yaşamadı.

Zaman İçindeki Volatilite: SQD.H 'un son bir yıldaki oynaklık değişimini belirlemek için Yetersiz veri.

Şirket Hakkında

Kuruldu	Çalışanlar	CEO	Web sitesi
1999	n/a	Andrew Morris	www.sqidiagnostics.com

SQI Diagnostics Inc. Temel Bilgiler Özeti

SQI Diagnostics'un kazançları ve gelirleri piyasa değeriyle nasıl karşılaştırılır?
SQD.H temel i̇stati̇sti̇kler
Piyasa değeri	CA$6.11m
Kazançlar(TTM)	-CA$19.14m
Gelir(TTM)	CA$3.05m

2.0x

P/S Oranı

-0.3x

F/K Oranı

SQD.H aşırı değerli mi?

Gerçeğe Uygun Değer ve değerleme analizine bakınız

Kazanç ve Gelir

En son kazanç raporundan temel karlılık istatistikleri (TTM)
SQD.H gelir tablosu (TTM)
Gelir	CA$3.05m
Gelir Maliyeti	CA$3.19m
Brüt Kâr	-CA$140.00k
Diğer Giderler	CA$19.00m
Kazançlar	-CA$19.14m

Son Raporlanan Kazançlar

Mar 31, 2023

Sonraki Kazanç Tarihi

n/a

Hisse başına kazanç (EPS)	-0.047
Brüt Marj	-4.60%
Net Kâr Marjı	-628.51%
Borç/Özkaynak Oranı	-103.3%

SQD.H uzun vadede nasıl bir performans gösterdi?

Geçmiş performansı ve karşılaştırmayı görün

SQD.H Stoklara Genel Bakış

Risk Analizi

SQI Diagnostics Inc. Rakipler

CNSX:SCYB

CA$4.8m

CNSX:ASEP

CA$3.8m

TSXV:FREQ

CA$6.6m

TSXV:EVMT

CA$11.2m

Fiyat Geçmişi ve Performans

Son Haberler & Güncellemeler

SQI Diagnostics Inc. Ordinary Shares to Be Deleted from OTC Equity

SQI Diagnostics Inc. Listing to Transfer to NEX Effective Feb. 20

Clive J. Beddoe Announces Resignation as Director of SQI Diagnostics Inc

SQI Diagnostics Expects its Common Shares to Continue to be Halted from Trading on Exchange and Ultimately Suspended and Delisted Following Completion of the Filing

SQI Diagnostics Inc. Announces Executive Changes

SQI Diagnostics Inc., Annual General Meeting, Jun 30, 2023

Recent updates

SQI Diagnostics Inc. Ordinary Shares to Be Deleted from OTC Equity

SQI Diagnostics Inc. Listing to Transfer to NEX Effective Feb. 20

Clive J. Beddoe Announces Resignation as Director of SQI Diagnostics Inc

SQI Diagnostics Expects its Common Shares to Continue to be Halted from Trading on Exchange and Ultimately Suspended and Delisted Following Completion of the Filing

SQI Diagnostics Inc. Announces Executive Changes

SQI Diagnostics Inc., Annual General Meeting, Jun 30, 2023

Second quarter 2023 earnings released: CA$0.009 loss per share (vs CA$0.007 loss in 2Q 2022)

Insufficient new directors

First quarter 2023 earnings released: CA$0.008 loss per share (vs CA$0.009 loss in 1Q 2022)

SQI Diagnostics Inc., Annual General Meeting, Apr 05, 2023

Full year 2022 earnings released: CA$0.048 loss per share (vs CA$0.031 loss in FY 2021)

SQI Installs Two Rali-Dx Systems in Toronto Hospitals to Fight the Growing Respiratory Health Crisis in Emergency Departments

SQI Diagnostics Inc. announced that it expects to receive CAD 1 million in funding

SQI Diagnostics Inc. announced that it expects to receive CAD 2 million in funding from Federal Economic Development Agency for Southern Ontario

SQI Diagnostics Announces Health Canada Approval of RALI-Dx Severity Triage Test

Third quarter 2022 earnings released: CA$0.012 loss per share (vs CA$0.002 loss in 3Q 2021)

Second quarter 2022 earnings: EPS in line with analyst expectations despite revenue beat

SQI Diagnostics (CVE:SQD) Has Debt But No Earnings; Should You Worry?

New York State Approves SQI Diagnostics' Exact Covid-19 Antibody Assay

First quarter 2022 earnings: EPS in line with analyst expectations despite revenue beat

Full year 2021 earnings: EPS in line with analyst expectations despite revenue beat

SQI Diagnostics Systems Inc. signed a definitive agreement to acquire all of the assets underlying Precision Biomonitoring Inc businesses from Precision Biomonitoring Inc. for CAD 6.825 million

SQI Diagnostics Inc. announced that it expects to receive CAD 6 million in funding

Third quarter 2021 earnings released: CA$0.002 loss per share (vs CA$0.005 loss in 3Q 2020)

Is SQI Diagnostics (CVE:SQD) Weighed On By Its Debt Load?

FDA Stops Emergency Use Authorization Review of SQI Diagnostics Inc. RALI-Dx IL-6 Severity Triage Test for Covid-19 Patients

CEO & Director Robert Chioini has left the company

Second quarter 2021 earnings released: CA$0.011 loss per share (vs CA$0.009 loss in 2Q 2020)

Health Check: How Prudently Does SQI Diagnostics (CVE:SQD) Use Debt?

Independent Director recently sold CA$56k worth of stock

Are Insiders Buying SQI Diagnostics Inc. (CVE:SQD) Stock?

First quarter 2021 earnings released: CA$0.012 loss per share (vs CA$0.009 loss in 1Q 2020)

Director exercised options to buy CA$705k worth of stock.

Director recently bought CA$660k worth of stock

New 90-day high: CA$0.40

SQI Diagnostics Inc., Annual General Meeting, Mar 31, 2021

Full year 2020 earnings released: CA$0.032 loss per share (vs CA$0.045 loss in FY 2019)

Is SQI Diagnostics Inc. (CVE:SQD) Popular Amongst Insiders?

SQI Diagnostics Announces Patient Enrollment Begins for its COVID-19 HOME Antibody Test Clinical Study

New 90-day high: CA$0.28

Independent Director exercised options to buy CA$1.7m worth of stock.

If You Had Bought SQI Diagnostics (CVE:SQD) Stock A Year Ago, You Could Pocket A 246% Gain Today

Is SQI Diagnostics (CVE:SQD) Using Debt Sensibly?

Sqi Diagnostics Inc. Updates Clinical Progress on Novel Covid-19 Tests Under Development for U.S. Fda Regulatory Submission

Third quarter earnings released

SQI Diagnostics Inc. Announces Executive Changes

New 90-day high - CA$0.21

Hissedar Getirileri

Fiyat Oynaklığı

Şirket Hakkında

SQI Diagnostics Inc. Temel Bilgiler Özeti

2.0x

-0.3x

Kazanç ve Gelir